TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic.
Karen Lisa SmithCarolyn Mead-HarveyGina L MazzaEileen H ShinnElizabeth S FrankMichelle E MeliskoCyd EatonYisi LiuJeannine M SalamoneTeri PollastroPatricia A SpearsNicole E CastonAntonio C WolffGabrielle Betty RocquePublished in: Cancer medicine (2024)
While pandemic-related anxiety was associated with diminished willingness to participate in trials, the leading reasons for reluctance to consider trial participation were unrelated to the pandemic but included worries about not getting the best treatment, side effects, and delaying care. Patients view trial modifications favorably, supporting continuation of these modifications, as endorsed by the National Cancer Institute and others.
Keyphrases
- sars cov
- coronavirus disease
- clinical trial
- phase iii
- phase ii
- end stage renal disease
- study protocol
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- palliative care
- physical activity
- papillary thyroid
- randomized controlled trial
- squamous cell carcinoma
- cross sectional
- squamous cell
- double blind
- chronic pain
- pain management
- childhood cancer